LIBERATE:米多君用于重症监护室早期脱离血管升压药支持的研究方案:随机对照试验方案
LIBERATE是一项多中心、平行组、盲法、随机安慰剂对照试验,纳入接受稳定或递减剂量静脉血管升压药的成人(≥18岁)危重症患者,随机接受米多君10 mg每8小时肠内给药或安慰剂至停用静脉血管升压药后24小时,主要结局为ICU住院时长,并评估90天全因死亡率、住院时长、静脉血管升压药支持时长、重新启用静脉血管升压药、ICU再入院率、不良事件及卫生经济学结局。
要点
- 纳入接受稳定或递减剂量静脉血管升压药的成人危重症患者。
- 米多君10 mg每8小时肠内给药,对照为安慰剂,用至停静脉升压药后24小时。
- 主要结局为ICU住院时长,次要结局包括90天全因死亡率和不良事件等。
核心结论
- LIBERATE将严格评估口服米多君对危重症患者ICU住院时长和静脉血管升压药支持的影响。
研究设计与样本
- 多中心、平行组、盲法、随机安慰剂对照试验。
- 招募年龄≥18岁、接受稳定或递减剂量静脉血管升压药的危重症患者。
- 随机接受米多君10 mg每8小时肠内给药或安慰剂,至停用静脉血管升压药后24小时。
关键数值与推荐
- 主要结局为ICU住院时长。
- 次要结局包括90天全因死亡率、住院时长、静脉血管升压药支持时长、重新启用静脉血管升压药、ICU再入院率和不良事件发生情况。
- 评估ICU、住院和医疗保健成本及成本效果等卫生经济学结局。
- 预先计划的亚组分析包括年龄、性别、衰弱、疾病严重程度、休克病因和合并症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous (IV) vasopressors to support hemodynamics are a primary indication for intensive care unit (ICU) admission. Utilization of oral vasopressor therapy may offer an alternative to IV vasopressor therapy in the ICU, thus decreasing the need for ICU admission. Oral vasopressors, such as midodrine, have been used for hemodynamic support in non-critically ill patients, but their evaluation in critically ill patients to potentially spare IV vasopressor therapy has been limited. METHODS: The LIBERATE study will be a multicenter, parallel-group, blinded, randomized placebo-controlled trial. It will recruit adult (i.e., age ≥ 18 years) critically ill patients receiving stable or decreasing doses of IV vasopressors. Eligible patients will be randomized to receive either midodrine 10 mg administered enterally every 8 h or placebo until 24 h post-discontinuation of IV vasopressors. The primary outcome will be ICU length of stay. Secondary outcomes include all-cause mortality at 90 days, hospital length of stay, length of IV vasopressor support, re-initiation of IV vasopressors, rates of ICU readmission, and occurrence of AEs. Health economic outcomes including ICU, hospital and healthcare costs, and cost-effectiveness will be evaluated. Pre-planned subgroup analyses include age, sex, frailty, severity of illness, etiology of shock, and comorbid conditions. DISCUSSION: LIBERATE will rigorously evaluate the effect of oral midodrine on duration of ICU stay and IV vasopressor support in critically ill patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT05058612 . Registered on September 28, 2021.
引用
- Opgenorth D, Baig N, Fiest K, et al. LIBERATE: a study protocol for midodrine for the early liberation from vasopressor support in the intensive care unit (LIBERATE): protocol for a randomized controlled trial. Trials. 2022. PMID: 35246227. doi:10.1186/s13063-022-06115-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。